您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Isoniazid
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Isoniazid
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Isoniazid图片
CAS NO:54-85-3
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
50mg电议

产品介绍

化学性质

Physical AppearanceA solid
StorageStore at -20°C
M.Wt137.14
Cas No.54-85-3
FormulaC6H7N3O
Solubilityinsoluble in EtOH; ≥50.9 mg/mL in H2O; ≥6.3 mg/mL in DMSO
Chemical Namepyridine-4-carbohydrazide
Canonical SMILESC1=CN=CC=C1C(=O)NN
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

Isoniazid acts as a front-line drug of choice for the treatment of tuberculosis by inhibiting cell wall lipid synthesis [1].

Isoniazid is a prodrug, activated by the mycobacterial catalase-peroxidase enzyme (KatG) in mycobacterium to an active form which disturbs cell wall lipid synthesis, and then exerts a lethal effect on an intracellular target [1].

InMycobacterium tuberculosis treated with Isoniazid at a concentration of 0.5 μg/ml, the cells stared losing their ability to synthesize mycolic acids immediately, and completely lost this ability after 60 min. The viability of the Isoniazid-treated cells remained, up to ~ 60 min of exposure, after which there was a gradual decline in the viability to ~ 18% after 180 min [2].

In a randomized clinical trial, Group I was assigned to Isoniazid 300 mg per day for 6 months and Group II was assigned to Isoniazid 300 mg per day plus Rifampin 600 mg per day for 3 months, for the treatment of latent tuberculosis infection. Hepatotoxicity was 44% in Group I and 29% in Group II [3].

References:

[1]. Mdluli K, Slayden R A, Zhu Y, et al. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science, 1998, 280(5369): 1607-1610.

[2]. Takayama K, Wang L, David H L. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability ofMycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 1972, 2(1): 29-35.

[3]. Geijo M P, Herranz C R, Vano D, et al. Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial. Enfermedades Infecciosas Y Microbiologia Clinica, 2007, 25(5): 300-304.